相关临床试验
0
0 进行中
药物批准
0
批准总数
监管机构
0
监管机构数
成立时间
N/A
暂无试验阶段数据
暂无试验数据
暂无试验数据
暂无批准数据
- NeuroSense Therapeutics' PrimeC demonstrated a statistically significant 33% reduction in ALS disease progression (p=0.007) and 58% improvement in survival rates in its Phase 2b PARADIGM trial. - The oral combination therapy showed differential expression of over 100 microRNAs, including downregulation of miR-199 and miR-181 associated with neuroinflammation and mortality. - Despite promising clinical results, the company faces financial constraints with only $3.4 million in cash and is pursuing a critical partnership to fund Phase 3 trials beginning in late 2025.
- NeuroSense Therapeutics will showcase new data from PrimeC's Phase 2b trial in ALS at the American Academy of Neurology Meeting on April 8, 2025, featuring presentations on clinical outcomes and microRNA biomarker findings. - PrimeC, a fixed-dose combination of ciprofloxacin and celecoxib, demonstrated safety, efficacy, and target engagement in an 18-month trial, showing marked reduction in ALS progression and significant changes in disease-related biomarkers. - The oral therapy employs a multi-targeted approach addressing several ALS pathways including motor neuron degeneration, inflammation, iron accumulation, and RNA regulation, potentially offering a disease-modifying treatment for the fatal neurodegenerative disease.
